American Association for Cancer Research

Enduring Materials

The AACR hosted its Ninth Annual Frontiers in Cancer Prevention Research Conference Nov. 7-10, 2010, at the Pennsylvania Convention Center in Philadelphia.

Experts estimate that nearly half of all cancers can be prevented based on what we know about smoking cessation, healthy lifestyles and the emerging science of chemoprevention. This annual conference is a one-of-a-kind meeting that draws hundreds of physicians, scientists and other health professionals and promotes public, academic, government and industry awareness of the vital importance of cancer prevention science in reducing cancer incidence and mortality. The theme of this year's conference was "Prevention: From Basic Science to Public Health Benefit."

The AACR provides the following recorded sessions for your reference:

Sunday, November 7, 2010
Opening Plenary Session

Distinguished Lecture on Targets for Cancer Prevention
Inflammation and cancer: Interweaving microRNA, innate immune, and p53 pathways
Curtis C. Harris, M.D., National Cancer Institute, Bethesda, MD

 

Monday, November 8, 2010

Plenary Session 1: Personalized Prevention
Nicotine-dependence pharmacogenetics: Implications for personalized therapy
Robert A. Schnoll, University of Pennsylvania, Philadelphia, PA

Selenium, genes, and cancer prevention
Jing Ma, M.D., Ph.D., Harvard Medical School, Boston, MA

ODC genotype as prognostic and predictive factors in colorectal carcinogenesis and prevention
Eugene W. Gerner, Ph.D., The University of Arizona Cancer Center, Tucson, AZ

Plenary Session 2: New Approaches to Identifying High-risk Populations
Somatic evolution and neoplastic progression in Barrett's esophagus: Lessons in space and time
Brian J. Reid, M.D., Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA

New insights into genetic susceptibility to breast cancer

Douglas Easton, Ph.D., University of Cambridge, Cambridge, United Kingdom

Ninth Annual AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research Lecture
Validating biomarkers to probe the etiology and prevention of hepatocellular carcinoma
John D. Groopman, Ph.D., Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

 

Tuesday, November 9, 2010

Plenary Session 3: Bioenergetics and Cancer
Exercise, adiposity and cancer
Anne McTiernan M.D., Ph.D., Fred Hutchinson Cancer Research Center, Seattle, WA

Plenary Session 3: Bioenergetics and Cancer
Obesity and mTORC1 signaling pathway
George Thomas, Ph.D., University of Cincinnati, Cincinnati, OH

Plenary Session 4: Understanding Neoplastic Progression: Questions and Controversies
Why do benign growths so often progress to malignant cancers?
John W. Pepper, Ph.D., The University of Arizona, Tucson, AZ

Cancer stem cells?
Simon Tavaré, Ph.D., University of Cambridge, Cambridge, United Kingdom
Tuesday, November 9, 2010

 

Wednesday, November 10, 2010

Plenary Session 5: Bringing Prevention and Early Detection to the Public: A Global Perspective
Global trends in cancer: The imperative for prevention
Michael J. Thun, M.D., M.S., American Cancer Society, Atlanta, GA

The Australian skin cancer prevention experience: Lessons learned and global challenges ahead
Craig Sinclair, M.P.P.M., Cancer Council Victoria, Carlton, VIC, Australia

From basic science to public health: The Canadian approach to oral leukoplakia
Miriam Rosin, Ph.D., British Columbia Cancer Research Center, Vancouver, Canada

Updated: Jan. 11, 2011